ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B cells"

  • Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting

    Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus

    Emily Blalock1, Chris Scharer2, Scott Jenks1, Jeremy Boss2 and Ignacio Sanz3, 1Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, 2Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, 3Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
  • Abstract Number: 1867 • 2013 ACR/ARHP Annual Meeting

    Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation

    Julia Sieber1, Capucine Daridon2, Simon Fillatreau3 and Thomas Dörner1, 1CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 2Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, 3German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany

    Background/Purpose: Beyond their antibody producing function, B cells have been shown to be potent antigen-presenting and cytokine-producing cells. In systemic lupus erythematosus (SLE), B cells…
  • Abstract Number: 919 • 2013 ACR/ARHP Annual Meeting

    B Cell Derived IFN-γ Contributes To The Negative Regulation Of T-Regulatory Cell Differentiation In Arthritis

    Susan Olalekan1, Yanxia Cao2 and Alison Finnegan2, 1Immunology, Rush University Medical Center, Chicago, IL, 2Dept of Medicine, Rush University Medical Center, Chicago, IL

    Background/Purpose: Depletion of B cells using a monoclonal antibody against CD20 expressed on mature B cells has proven efficacious in patients with rheumatoid arthritis (RA).…
  • Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting

    B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus

    Michael Faludi1, Christian A. Pineau2, Evelyne Vinet1, Ann E. Clarke3, Sasha Bernatsky4, Joyce Rauch2 and Emil P. Nashi5, 1McGill University Health Center, Montreal, QC, Canada, 2Rheumatology, McGill University Health Center, Montreal, QC, Canada, 3Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 4Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, 5Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada

    Background/Purpose: B cells are central to SLE.  Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development.  Murine…
  • Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting

    Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis

    Rohit Aggarwal1, Chester V. Oddis2, Erich R Wilkerson3, Diane Koontz4, Ilinca D. Metes5, Ann M. Reed6, Dana P. Ascherman7 and Marc C. Levesque8, 1Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 3Medicine, University of Pittsburgh, Pittsburgh, PA, 4Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Mayo Clinic, Rochester, MN, 7Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…
  • Abstract Number: 920 • 2013 ACR/ARHP Annual Meeting

    Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis

    Mattias Svensson1, Kersti Månsson1, Karin Andersson1, Mats Bemark2, Mikael Brisslert1 and Maria Bokarewa1, 1Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 2Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Signaling through the tyrosine kinase receptor Flt3 plays an important role in early B-cell development. Mice lacking either Flt3 or its ligand (Flt3L) have…
  • Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting

    Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation

    Franziska Matzkies1, Anthony DeFranco2, Andrew J. Gross3, Maria Dall'era4 and Michelle Hermiston5, 1Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, 2Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, 3Medicine, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
  • Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis:  Results From a Phase 3 Multicenter, Randomized, Double-Blind Study

    MC Genovese1, Gregg J. Silverman2, Paul Emery3, Ramesh Gupta4, Anne Gill5, Wendy J. Komocsar5, Melissa Veenhuizen5, Li Xie5, Pierre-Yves Berclaz5 and Chin Lee5, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2Rheumatology, NYU School of Medicine, New York, NY, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Private Practice, Memphis, TN, 5Eli Lilly and Company, Indianapolis, IN

     Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…
  • Abstract Number: 921 • 2013 ACR/ARHP Annual Meeting

    Blocking The Complement Receptor 2 (CR2) Ligand-Receptor Interaction With a Novel Mouse Anti-Mouse CR2 Monoclonal Antibody Decreases Antigen-Specific Humoral Immune Responses and The Evolution Of Collagen-Induced Arthritis

    Rosa Rodriguez1, Liudmila Kulik1, Joshua Thurman2, Jonathan Hannan1, Steve Tomlinson3 and V. Michael Holers1, 1Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 2Renal Division, University of Colorado School of Medicine, Aurora, CO, 3Microbiology and Immunology, Medical University of South Carolina, Charleston, NC

    Background/Purpose: The CR2/CD19 complex on B cells serves as a co-receptor for membrane IgM and amplifies B cell responses through physical associations of the bound…
  • Abstract Number: 36 • 2013 ACR/ARHP Annual Meeting

    IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus

    Joan E. Wither1, Nan-Hua Chang2, Timothy Li3, Julie Kim4, Carolina Landolt-Marticorena5, Paul R. Fortin6, Dafna D. Gladman7 and Murray B. Urowitz8, 11E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 6Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization. …
  • Abstract Number: 2529 • 2012 ACR/ARHP Annual Meeting

    Molecular Mechanism of IgG4 Class Switch Recombination in IgG4-Related Disease

    Hiroto Tsuboi1, Mana Iizuka1, Hiromitsu Asashima1, Sayaka Tsuzuki1, Yuya Kondo1, Akihiko Tanaka2, Masafumi Moriyama2, Isao Matsumoto1, Seiji Nakamura2 and Takayuki Sumida1, 1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Faculty of Dental Science, Kyushu University, Fukuoka, Japan

    Background/Purpose: IgG4-related disease (IgG4-RD) is a new disease entity characterized by high serum IgG4 levels, IgG4-positive plasmacytic infiltration and fibrosis in various organs. Although the…
  • Abstract Number: 1767 • 2012 ACR/ARHP Annual Meeting

    Circulating Plasmablasts As a Source of Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis

    Priscilla Kerkman, Ellen I.H. van der Voort, Leendert A. Trouw, Tom W.J. Huizinga, René E.M. Toes and Hans Ulrich Scherer, Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anti citrullinated protein antibodies (ACPA) are highly specific for rheumatoid arthritis (RA) and predict disease onset and severity. Accumulating evidence indicates that ACPA could…
  • Abstract Number: 1207 • 2012 ACR/ARHP Annual Meeting

    Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells

    Ezinma Ezealah1, Jennifer Hossler1, Jamie Biear1, Christopher A. Cistrone1, Teresa Owen1, Nida Meednu1, Kelly Callahan1, Arumugam Palanichamy1, Ignacio Sanz2, Allen P. Anandarajah1, Ralf G. Thiele1, Darren Tabechian3, R. John Looney1 and Jennifer H. Anolik1, 1Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Rheumatology, Emory University, Atlanta, GA, 3Allergy/Immun/Rheumatology, Univ of Rochester Schl of Med, Rochester, NY

    Background/Purpose:  Serum receptor activator of NFkB ligand (RANKL) and its natural decoy receptor, osteoprotegerin (OPG), play key roles in osteoclast activation. In a group of…
  • Abstract Number: 316 • 2012 ACR/ARHP Annual Meeting

    The Interleukin-10 (IL-10) Producing Regulatory B Cell (“B10 cell”) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (pSLE)

    Ioannis Kalampokis1, Jeffrey A. Dvergsten2 and Thomas Tedder3, 1Immunology and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 2Pediatrics Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 3Department of Immunology, Duke University Medical Center, Durham, NC

    Background/Purpose: pSLE and JDM are multisystem inflammatory diseases, whereas juvenile idiopathic arthritis (JIA) is typically an organ-limited disease. “B10 cells”, a rare subset of human…
  • Abstract Number: 2453 • 2012 ACR/ARHP Annual Meeting

    The Role of Bob1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity

    Nataliya Yeremenko1, Tineke Cantaert1, Melissa N. van Tok2, Ioana Gofita1, Juan D. Canete3, Paul P. Tak4, Hergen Spits5 and Dominique L. Baeten4, 1Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 3Arthritis Unit. Rheumatology Department, Hospital Clínic, Barcelona, Spain, 4Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology